You may remember that in November we posted the latest news about the RTOG 0825 trial – the largest trial that is studying the benefit of Avastin (bevacizumab) in patients who have been diagnosed with a GBM4. We said that there would be more news to follow – and here it is, hot off the press from ASCO, the American Society of Clinical Oncology.
As always it is checks and balances. The results in November showed that this therapy prolongs progression free survival, but that it does not change overall survival. The latest trial results show that Avastin causes a greater decline in global neurocognitive function and that symptoms and quality of life for patients receiving this therapy were considerably worse. So whilst there maybe a longer period before the tumour progresses, this is at considerable cost. The symptom burden, so tumour and treatment related symptoms and symptoms that impact on everyday life were worse for patients on Avastin.
For more information have a look here: